Therapeutic drug monitoring of felbamate;Suivi thérapeutique pharmacologique du felbamate

Therapie

Volumn 65, Issue 1, 2010, Pages 35-38

  Tribut, Olivier ^a   Bentué Ferrer, Danièle ^a   Verdier, Marie Clémence ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Felbamate; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; DRUG METABOLITE; ETHINYLESTRADIOL; FELBAMATE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ANOREXIA; APLASTIC ANEMIA; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG URINE LEVEL; FOCAL EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; KIDNEY FUNCTION; LENNOX GASTAUT SYNDROME; LIQUID CHROMATOGRAPHY; LIVER; LIVER FAILURE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; SHORT SURVEY; ULTRAVIOLET SPECTROSCOPY; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77949434581     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2009068     Document Type: Article

References (29)

1. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit 2007; 13: RA1-7
2. French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Report of the quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52: 1540-1545
3. Felbamate Study Group in the Lennox-Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 1993; 328: 29-33
4. Résumé des Caractéristiques du Produit : Taloxa. Dictionnaire Vidal, édition 2008
5. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991; 41: 1785-1789
6. Sachdeo R, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-392
7. Bourgeois BFD. Felbamate. Semin Pediatr Surg 1997; 4: 3-8
8. Potschka H, Fedrowitz M, LöscherW. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327: 173-176
9. Kapetanovic IM, Torchin CD, Thompson CD, et al. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab Dispos 1998; 26: 1089-1095
10. Glue P, Sulowicz W, Colucci R, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol 1997; 44: 91-93
11. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-283
12. Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy 1997; 10: 26-31
13. Ettinger AB, Jandorf L, Berdia A, et al. Felbamate-induced headache. Epilepsia 1996; 37: 503-505
14. Banfield CR, Zhu GR, Jen JF, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using non-linear mixed effects modeling. Ther Drug Monit 1996; 18: 19-29
15. Kelley MT, Walson PD, Cox S, et al. Population pharmacokinetics of felbamate in children. Ther Drug Monit 1997; 19: 29-36
16. Richens A, Banfield CR, Salfi M, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997; 44: 129-134
17. Fuerst RH, Graves NM, Leppik IE, et al. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia 1988; 29: 488-491
18. Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther 1994; 56: 494-502
19. Hooper WD, Franklin ME, Glue P, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Epilepsia 1996; 37: 91-97
20. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991; 32: 130-132
21. Contin M, Riva R, Albani F, et al. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit 1999; 21: 604-608
22. Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995; 58: 523-531
23. Annesley TM, Clayton LT. Determination of felbamate in human serum by high-performance liquid chromatography. Ther Drug Monit 1994; 16: 419-424
24. Behnke CE, Reddy MN. Determination of felbamate concentration in pediatric samples by high-performance liquid chromatography. Ther Drug Monit 1997; 19: 301-306
25. Remmel RP, Miller SA, Graves NM. Simultaneous assay of felbamate plus carbamazepine, phenytoin, and their metabolites by liquid chromatography with mobile phase optimisation. Ther Drug Monit 1990; 12: 90-96
26. Romanyshyn LA, Wichmann JK, Kucharczyk N, et al. Simultaneous determination of felbamate, primidone, phenobarbital, carbamazepine, two carbamazepine metabolites, phenytoin, and one phenytoin metabolite in human plasma by high-performance liquid chromatography. Ther Drug Monit 1994; 16: 90-99
27. Shihabi ZK, Oles KS. Felbamate measured in serum by two methods: HPLC and capillary electrophoresis. Clin Chem 1994; 40: 1904-1908
28. Rifai N, Fuller D, Law T, et al. Measurement of felbamate by wide-bore capillary chromatography and flame ionization detection. Clin Chem 1994; 40: 745-748
29. Thompson CD, Barthen MT, Hopper DW, et al. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 1999; 40: 769-776